However, some individuals may notice temporary changes in sleep patterns early on, often related to reduced calorie intake, nausea, or mild fatigue
The foundational characterization appeared in European Journal of Endocrinology in 1998, reporting selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a) without significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses 200-fold above the GH-releasing ED50 in preclinical models
Unapproved products are risky not only because they havent been reviewed by the FDA, but because theres no way to know their potency, possible contamination, or potential dosing errors
*Average weight-loss figures reflect randomized trials of the FDA-approved branded molecules (SURMOUNT for tirzepatide, STEP for semaglutide), not compounded products, and individual results vary